SHP-2 tyrosine phosphatase in human diseases

International Journal of Clinical and Experimental Medicine

Volumn 2, Issue 1, 2009, Pages 17-25

  Zheng, Hong ^a   Alter, Shawn ^a   Qu, Cheng Kui ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

SHP 2; Src homology 2 domain; Tyrosine phosphatase

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 2;

APOPTOSIS; CARCINOGENESIS; CATALYSIS; CELL FUNCTION; CELL NUCLEUS; CONGESTIVE CARDIOMYOPATHY; CYTOPLASM; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GASTRITIS; GENE ACTIVATION; GENE DELETION; GENE MUTATION; HUMAN; LEOPARD SYNDROME; LEUKEMIA; LEUKEMOGENESIS; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; NERVE CELL NECROSIS; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALIA;

EID: 65549086595     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Arrandale JM, Gore-Willse A, Rocks S, Ren JM, Zhu J, Davis A, Livingston JN and Rabin DU. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 1996; 271: 21353-21358.
2. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS and Pawson T. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. Embo J 1997; 16: 2352-2364.
3. Yang W, Klaman LD, Chen B, Araki T, Harada H, Thomas SM, George EL and Neel BG. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell 2006; 10: 317-327.
4. Qu CK, Nguyen S, Chen J and Feng GS. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 2001; 97: 911-914.
5. Qu CK, Shi ZQ, Shen R, Tsai FY, Orkin SH and Feng GS. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol 1997; 17: 5499-5507.
6. Qu CK, Yu WM, Azzarelli B, Cooper S, Broxmeyer HE and Feng GS. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol 1998; 18: 6075-6082.
7. Ke Y, Zhang EE, Hagihara K, Wu D, Pang Y, Klein R, Curran T, Ranscht B and Feng GS. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol 2007; 27: 6706-6717.
8. Kontaridis MI, Yang W, Bence KK, Cullen D, Wang B, Bodyak N, Ke Q, Hinek A, Kang PM, Liao R and Neel BG. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation 2008; 117: 1423-1435.
9. Fornaro M, Burch PM, Yang W, Zhang L, Hamilton CE, Kim JH, Neel BG and Bennett AM. SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J Cell Biol 2006; 175: 87-97.
10. Ke Y, Lesperance J, Zhang EE, Bard-Chapeau EA, Oshima RG, Muller WJ and Feng GS. Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J Biol Chem 2006; 281: 34374-34380.
11. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ and Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441-450.
12. Barford D and Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998; 6: 249-254.
13. Zhao R, Fu X, Teng L, Li Q and Zhao ZJ. Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains. J Biol Chem 2003; 278: 42893-42898.
14. Neel BG, Gu H and Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28: 284-293.
15. Qu CK. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 2002; 1592: 297-301.
16. Maegawa H, Hasegawa M, Sugai S, Obata T, Ugi S, Morino K, Egawa K, Fujita T, Sakamoto T, Nishio Y, Kojima H, Haneda M, Yasuda H, Kikkawa R and Kashiwagi A. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. J Biol Chem 1999; 274: 30236-30243.
17. Yuan L, Yu WM, Yuan Z, Haudenschild CC and Qu CK. Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response. J Biol Chem 2003; 278: 15208-15216.
18. Yuan L, Yu WM and Qu CK. DNA damage-induced G2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J Biol Chem 2003; 278: 42812-42820.
19. Yuan L, Yu WM, Xu M and Qu CK. SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively. J Biol Chem 2005; 280: 42701-42706.
20. Jakob S, Schroeder P, Lukosz M, Buchner N, Spyridopoulos I, Altschmied J and Haendeler J. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J Biol Chem 2008; 283: 33155-33161.
21. Salvi M, Stringaro A, Brunati AM, Agostinelli E, Arancia G, Clari G and Toninello A. Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. Cell Mol Life Sci 2004; 61: 2393-2404.
22. Aoki Y, Huang Z, Thomas SS, Bhide PG, Huang I, Moskowitz MA and Reeves SA. Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. Faseb J 2000; 14: 1965-1973.
23. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS and Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465-468.
24. Noonan JA. Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila) 1994; 33: 548-555.
25. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD and Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103: 2325-2331.
26. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD and Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148-150.
27. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Arico M, Masera G, Basso G, Sorcini M, Gelb BD and Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004; 104: 307-313.
28. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR and Neel BG. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004; 64: 8816-8820.
29. Keilhack H, David FS, McGregor M, Cantley LC and Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 2005; 280: 30984-30993.
30. Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriyama S, Kawame H, Kamasaki H, Yamanaka T, Takada F, Nishio K, Sakurai M, Tamai H, Nagashima T, Suzuki Y, Kure S, Fujii K, Imaizumi M and Matsubara Y. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 2005; 50: 192-202.
31. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA and Neel BG. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004; 10: 849-857.
32. Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M and Kapur R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005; 105: 3737-3742.
33. Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW and Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005; 106: 311-317.
34. Yu WM, Daino H, Chen J, Bunting KD and Qu CK. Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling. J Biol Chem 2006; 281: 5426-5434.
35. Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, Akashi K, Gilliland DG and Neel BG. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005; 7: 179-191.
36. Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, Kondo S and Hatakeyama M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 2008; 27: 3508-3515.
37. Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M and Fryns JP. PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002; 39: 571-574.
38. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A and Dallapiccola B. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002; 71: 389-394.
39. Kontaridis MI, Swanson KD, David FS, Barford D and Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006; 281: 6785-6792.
40. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M and Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683-686.
41. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688-694.
42. Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ and Qu CK. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 2007; 109: 778-785.
43. Muller JP, Schonherr C, Markova B, Bauer R, Stocking C and Bohmer FD. Role of SHP2 for FLT3-dependent proliferation and transformation in 32D cells. Leukemia 2008; 22: 1945-1948.
44. Zhan Y and O'Rourke DM. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res 2004; 64: 8292-8298.
45. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G and Chiarle R. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007; 67: 4278-4286.
46. Ostman A, Hellberg C and Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006; 6: 307-320.
47. Aoki Y, Niihori T, Narumi Y, Kure S and Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008; 29: 992-1006.
48. Gelb BD and Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet 2006; 15 Spec No 2: R220-226.
49. Bennett AM, Tang TL, Sugimoto S, Walsh CT and Neel BG. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A 1994; 91: 7335-7339.
50. Li W, Nishimura R, Kashishian A, Batzer AG, Kim WJ, Cooper JA and Schlessinger J. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol 1994; 14: 509-517.
51. Yu WM, Hawley TS, Hawley RG and Qu CK. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 2003; 22: 5995-6004.
52. Fragale A, Tartaglia M, Wu J and Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004; 23: 267-277.
53. Chen J, Yu WM, Bunting KD and Qu CK. A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival. Oncogene 2004; 23: 3659-3669.
54. Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, Feng GS and Wang D. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 2003; 278: 16520-16527.
55. Chughtai N, Schimchowitsch S, Lebrun JJ and Ali S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem 2002; 277: 31107-31114.
56. Yu CL, Jin YJ and Burakoff SJ. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J Biol Chem 2000; 275: 599-604.
57. Laux D, Kratz C and Sauerbrey A. Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome. J Pediatr Hematol Oncol 2008; 30: 602-604.
58. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, Lopez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M and Gelb BD. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39: 1007-1012.
59. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T and Matsuoka R. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39: 1013-1017.
60. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K and Kratz CP. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38: 331-336.
61. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD and Tartaglia M. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006; 79: 129-135.
62. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D and Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007; 39: 75-79.
63. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG and Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39: 70-74.
64. Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, Look AT, Kucherlapati R, Kern SE, Meyerson M and Neel BG. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer 2008; 47: 253-259.